Chemed Corporation (CHE) Stock Analysis

Company Overview

Chemed Corporation functions primarily within the healthcare sector, specifically operating in the medical care facilities industry by providing hospice and palliative care services to patients across the United States. This operational scope is executed through a comprehensive network that includes physicians, registered nurses, home health aides, social workers, clergy, and volunteers working in partnership with doctors. The organization employs a substantial workforce of 15,811 individuals to support its extensive service delivery model. With a market capitalization of $5.20 billion and trailing twelve-month revenue of $2.53 billion, Chemed represents a significant entity in the healthcare landscape. These valuation and revenue figures indicate that the company has established a solid market position and possesses the financial scale to sustain operations within the competitive medical care facilities sector.

Financial Health

The company reported trailing twelve-month revenue of $2.53 billion, generated net income of $265.24 million, and achieved EBITDA of $404.40 million. The substantial gap between the total revenue figure and the net income reveals a cost structure where operating expenses, including labor and administrative costs, consume approximately 89.5% of total revenue before accounting for interest and taxes. Free cash flow stood at $246.01 million, which indicates the company generates sufficient cash from operations to cover capital expenditures and maintain financial flexibility for ongoing business needs. Profitability is assessed through three distinct margins: a gross margin of 32.5%, an operating margin of 16.6%, and a profit margin of 10.5%. The gross margin reflects the efficiency of direct service delivery, while the operating margin demonstrates control over overhead costs, and the profit margin shows the final bottom-line profitability after all expenses. Regarding liquidity and leverage, the company holds $74.52 million in cash against total debt of $143.76 million, resulting in a debt-to-equity ratio of 14.68. This leverage profile suggests a balanced balance sheet where the company utilizes debt but maintains manageable obligations relative to its equity base. Short-term liquidity is supported by a current ratio of 1.05, indicating that current assets slightly exceed current liabilities to meet short-term obligations. Management effectiveness is highlighted by a return on equity of 25.3% and a return on assets of 13.4%, metrics that demonstrate the company's ability to generate strong returns on the capital invested by shareholders and across its asset base.

Valuation Assessment

Valuation metrics show a trailing P/E ratio of 20.08 compared to a forward P/E of 13.85. The significant difference between these two ratios implies that the market expects earnings to grow substantially in the future, causing the forward multiple to be lower than the historical trailing multiple. The price-to-book ratio stands at 5.16, which indicates that the market values the company at a significant premium over its tangible book value, reflecting intangible assets and brand strength. Alternative valuation measures include a price-to-sales ratio of 2.06 and an EV/EBITDA of 12.72, suggesting the stock is priced at a moderate multiple relative to its sales and earnings power. The stock has traded between a 52-week low of $365.25 and a 52-week high of $623.61. Based on the current valuation metrics provided, the stock is currently trading at 46.0% below the 52-week high and 46.0% above the 52-week low. The beta value is recorded at 0.46, meaning the stock exhibits lower price volatility relative to the broader market and tends to move less aggressively than the overall market index.

Growth & Income

Recent growth performance shows a revenue growth rate of -0.1% year-over-year and an earnings growth rate of -9.1% year-over-year. The earnings growth rate is significantly slower than the revenue growth rate, which implies that the company is currently experiencing a contraction in profitability that is more severe than the slight decline in top-line sales. As a dividend payer, Chemed offers a dividend yield of 0.6% with a payout ratio of 12.0%. This low payout ratio suggests that the dividend is highly sustainable given the company's earnings, as only a small fraction of profits is distributed to shareholders while the majority is retained for operations. Given the negative growth rates, the company is currently prioritizing capital retention for operational stability rather than aggressive expansion or high dividend payouts. The overall growth and income profile reflects a mature, cash-flow positive business that is currently navigating a period of minor revenue stagnation and earnings compression while maintaining a highly conservative dividend policy.